Evofem Biosciences, Inc. (NASDAQ:EVFM) is reporting second quarter financial results on Tuesday 4th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, EVFM is expected to report 2Q20 loss of $ 0.37 per share
For the full year, analysts anticipate top line of $ 7.97 million, while looking forward to loss of $ 1.65 per share bottom line.
Previous Quarter Performance
Evofem Biosciences, Inc. communicated loss for the first quarter of $ 0.40 per share, from the revenue of . The quarterly earnings while revenues compared with the same quarter last year.
According to street consensus, loss of $ 0.32 was expected per share The bottom line results missed street analysts by $ 0.08 or 25 percent, at the same time, top line results analysts by $ 19 million or .
Stock Performance
According to the previous trading day, closing price of EVFM was $ 3.20, representing a 17.22 % increase from the 52 week low of $ 2.73 and a 57.33 % decrease over the 52 week high of $ 7.50.
The company has a market capital of $ 251.83 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”EVFM” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 9th June 2020, maintained by HC Wainwright at Buy rating, with $ 9.00 target price.
Conference Call
Evofem Biosciences, Inc. will be hosting a conference call at 11:00 AM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.evofem.com
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes womens sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis.
